Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down as the Danish drug giant faces increased competition for its ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will resign due to the company's declining market position in obesity drugs. Despite previous successes with Wegovy, shares have dropped amid intense ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk board and Lars Fruergaard Jorgensen have jointly concluded that ...

The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post “for a period to support a smooth ...

Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its ...

A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...